Related Experiment Video
Updated: Aug 9, 2026
09:24
O-Ring Aortic Banding Versus Traditional Transverse Aortic Constriction for Modeling Pressure Overload-Induced Cardiac Hypertrophy
Published on: October 6, 2022
Cost-effectiveness of three transdermal nitroglycerin controlled-release systems
1Rescon, Inc, Tysons Corner, Virginia.
Clinical Therapeutics
|January 1, 1988
Summary
Transdermal nitroglycerin systems (TDN, ND II, NTS) were analyzed for cost-effectiveness. TDN demonstrated superior adhesion and tolerability, ultimately proving more cost-effective despite initial higher costs for other systems.
Area of Science:
- Pharmacoeconomics
- Clinical Pharmacology
- Dermatology
Background:
- Transdermal nitroglycerin systems are used for various cardiovascular conditions.
- Comparing different transdermal drug delivery systems is crucial for optimizing patient care and healthcare costs.
- Adhesive properties, patient preference, and skin tolerability significantly impact the overall effectiveness and cost of transdermal therapies.
Purpose of the Study:
- To conduct a cost-effectiveness analysis of three transdermal nitroglycerin systems: TDN, ND II, and NTS.
- To identify the system that achieves treatment objectives at the lowest overall cost.
- To evaluate the influence of adhesion, patient preference, and skin tolerability on cost-effectiveness.
Main Methods:
- Cost-effectiveness analysis using data from two comparative studies.
- Evaluation of adhesive properties, patient preferences, and skin tolerability.
- Multivariate regression analysis to assess cost savings and adverse event impact.
Main Results:
- TDN showed better adhesion and tolerability than ND II, resulting in 2.8%-4.4% savings.
- Multivariate analysis indicated potential savings of 11%-12.7% with TDN over ND II.
- While NTS had lower direct costs, high adverse reaction rates (42%) and withdrawals (64%) negated its cost advantage compared to TDN (2% adverse reactions, 0% withdrawals).
Conclusions:
- The superior adhesion and tolerability of the TDN system contribute to its overall cost-effectiveness.
- Adverse reactions and patient adherence significantly influence the true cost of transdermal therapies.
- TDN is a more cost-effective transdermal nitroglycerin option when considering comprehensive patient outcomes and total healthcare costs.
More Related Videos
08:21Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
Published on: July 21, 2023
06:33Fabrication of Dissolvable Microneedle Patches Loaded with α-Lactalbumin Nanomicelles for Transdermal Capsaicin Delivery and Adipose Tissue Reduction
Published on: December 30, 2025
Related Concept Videos
01:18Drug Delivery: Enteral Route
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Drugs in...
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:18Transdermal Drug Delivery Systems
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...